Latest Production Development News

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.

Talga Group has achieved critical milestones with environmental permits and a 25-year mining concession for its Nunasvaara South graphite mine, alongside securing a €70 million EU Innovation Fund grant for its Luleå Anode Refinery, positioning it at the forefront of Europe's battery materials supply chain.

Oakridge International Limited reports a strong quarterly performance driven by increased contracted orders, strategic partnerships, and technological innovation, positioning the company for sustained growth into 2025.

DTI Group Limited has inked a global Master Framework Agreement with Siemens Mobility GmbH, streamlining worldwide purchasing and opening doors to new rail and bus sector projects. Despite a modest cash balance, DTI is advancing its flagship software, positioning itself for growth.

RooLife Group Ltd (ASX:RLG) reports a remarkable 144% jump in Q2 FY25 sales revenue, driven by new online stores and strategic market entries into China and India. The company’s own branded health and wellness products are central to its growth strategy.

Inventis Limited reported robust Q2 progress with over $5.7 million in confirmed orders and a $2.5 million capital raise underway in the US, signaling strong momentum in its technology-driven growth strategy.

Structural Monitoring Systems plc has raised $8.7 million and implemented a major cost restructuring, positioning itself for profitable growth with strong sales momentum in its avionics and sensor technology segments.

Nova Eye Medical Limited is raising A$6.6 million to strengthen its financial position following resolved supply chain disruptions, while reporting strong sales growth and nearing profitability in its glaucoma division.

Nova Eye Medical has completed a $6.6 million placement to fund growth initiatives, supported by strong global sales growth and a major shareholder commitment. The capital raise aims to bolster sales teams and product development as the company targets profitability in its glaucoma division.

Nova Eye Medical reports a robust 39% increase in global sales driven by strong U.S. market demand and secures $6.6 million in fresh capital to fuel expansion and product development.

BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.

Zimi Limited has secured $2.495 million through a capital raising, appointed new board members, and initiated cost-saving measures exceeding $400,000 annually, while navigating a compliance issue affecting sales to a major distributor.